Leerink analyst Thomas Smith downgraded Rapt Therapeutics (RAPT) to Market Perform from Outperform with a $58 price target after GSK entered into an agreement to acquire all the outstanding shares of Rapt for $58 per share in cash
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- Rapt Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Rapt Therapeutics downgraded to Hold from Buy at TD Cowen
- Rapt downgraded to Market Perform from Outperform at LifeSci Capital
- Midday Fly By: Netflix and Warner amend deal, GSK to acquire Rapt
- Rapt Therapeutics downgraded to Neutral from Buy at H.C. Wainwright